Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B
- Resource Type
- Authors
- Hong-Ying Pan; Xiaoling Su; Yongxi Tong; Deying Chen; Zeyu Sun; Meijuan Chen; Hai-Jun Huang; Lanjuan Li; Jia-Jie Zhang
- Source
- Scientific Reports
- Subject
- 0301 basic medicine
Adult
Liver Cirrhosis
Male
medicine.medical_specialty
Metabolite
Inflammation
Phosphatidylserines
Biology
Phosphatidylinositols
Gastroenterology
Severity of Illness Index
Article
Cohort Studies
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Hepatitis B, Chronic
Fibrosis
Internal medicine
Severity of illness
Metabolome
medicine
Humans
Multidisciplinary
medicine.diagnostic_test
Lysophosphatidylcholines
Hepatitis B
Middle Aged
medicine.disease
030104 developmental biology
chemistry
Liver
Liver biopsy
Immunology
Phosphatidylcholines
Biomarker (medicine)
030211 gastroenterology & hepatology
Female
medicine.symptom
Biomarkers
- Language
- English
- ISSN
- 2045-2322
Chronic HBV (CHB) infected patients with intermediate necroinflammation and fibrosis are recommended to receive antiviral treatment. However, other than liver biopsy, there is a lack of sensitive and specific objective method to determine the necroinflammation and fibrosis stages in CHB patients. This study aims to identify unique serum metabolomic profile associated with histological progression in CHB patients and to develop novel metabolite biomarker panels for early CHB detection and stratification. A comprehensive metabolomic profiling method was established to compare serum samples collected from health donor (n = 67), patients with mild (G